The total number of records retrieved from this search are 150. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_568	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with PKA catalytic subunit siRNA and scramble siRNA (siPKA-1)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result62% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_569	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with PKA catalytic subunit siRNA and scramble siRNA (siPKA-2)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result57% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_570	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with PKA catalytic subunit siRNA and scramble siRNA (siPKA-3)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result65% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_571	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result50% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_572	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.001 PFU/cell	In-vitro result70% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_573	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.001 PFU/cell	In-vitro result100% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_574	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.01 PFU/cell	In-vitro result39% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_575	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.01 PFU/cell	In-vitro result100% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_576	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result22% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_577	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result92% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_578	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration1 PFU/cell	In-vitro result20% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_579	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration1 PFU/cell	In-vitro result80% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_580	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89(10 μM) for 1 hour	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result20% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_581	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNon toxic to human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result75% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_592	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1001)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result100% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_593	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1002)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result70% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_594	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1003)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result90% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_595	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1001) and with H89(10 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result60% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_596	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1002) and with H89(10 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result45% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_597	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with small interfering RNA (siRNAs) against Epac1 (siEpac1003) and with H89(10 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityVery small toxicity towards human immortalized liver cell line L-02	AssayMTT assay	In-vitro virus concentration10 PFU/cell	In-vitro result75% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedJNK, mitochondrial apoptotic pathway, Caspase-3/7, Caspase-9 and Caspase-8 (active caspases activates downstream apoptotic pathway) are activated	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_598	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with ESI-09 and with H89(10 μM)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result60% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here) were inhibited by H89	Clinical trialNA	PMID27374176
IDOV_599	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with ESI-09	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma cell line	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 PFU/cell	In-vitro result80% cancer cell viability at 72 hours post-infection	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedESI-09 abrogates the activities of Caspase-3/9/8 induced by H89/M1 combination treatment.	Immunogenic effectM1 upregulated transcriptional ISGs (329 shown here)	Clinical trialNA	PMID27374176
IDOV_1156	Virus nameHerpes simplex virus	Virus strainNV1020	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineColon carcinoma cell line	Cell lineHCT-116	Concentration of cell line1.25E+3 cells per well	In-vitro toxicityNA	AssayWST-1 assay	In-vitro virus concentration1 × 10⁶ pfu/ml	In-vitro result70% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID17117895
IDOV_2760	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro resultNo cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2761	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.5 MOI	In-vitro resultModerate cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2762	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro resultModerate cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2763	Virus nameAdenovirus	Virus strainZD55-lipocalin2	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B55 gene and insertion of lipocalin2 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro resultAll cells are died	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInducing apoptosis and decreasing microvessel density of tumor	Immunogenic effectNA	Clinical trialNA	PMID23464854
IDOV_2819	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2820	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2821	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2834	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result60% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2835	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2836	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+6 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectUpregulation of immune related antigens and cytokines like IFN-gamma, IP-10, MCP-1, MCP-3	Clinical trialNA	PMID23531320
IDOV_2843	Virus nameVaccinia virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (5.0E+6 cells)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 42 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID23531320
IDOV_2972	Virus nameTanapoxvirus	Virus strainTPV-delta66R-mMCP-1	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of 66R and insertion of MCP-1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude Foxn1 mice xenograft for HCT-116 (5.0E+6)	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 50mm after 36 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectTriggers activation of Ipaf inflamosome, IL-beta, TNF-alpha, IL-6 and IL-8	Clinical trialNA	PMID25887490
IDOV_2973	Virus nameTanapoxvirus	Virus strainTPV-delta66R/flic	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of 66R and insertion of flic gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude Foxn1 mice xenograft for HCT-116 (5.0E+6)	In-vivo virus concentration5 × 10⁶ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 50mm after 36 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectTriggers activation of Ipaf inflamosome, IL-beta, TNF-alpha, IL-6 and IL-8	Clinical trialNA	PMID25887490
IDOV_2974	Virus nameTanapoxvirus	Virus strainTPV-delta66R	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of 66R	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude Foxn1 mice xenograft for HCT-116 (5.0E+6)	In-vivo virus concentration5 × 10⁶ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 50mm after 36 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectTriggers activation of Ipaf inflamosome, IL-beta, TNF-alpha, IL-6 and IL-8	Clinical trialNA	PMID25887490
IDOV_2975	Virus nameTanapoxvirus	Virus strainTPV-delta2L	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of 2L gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude Foxn1 mice xenograft for HCT-116 (5.0E+6)	In-vivo virus concentration5 × 10⁶ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 50mm after 36 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectTriggers activation of Ipaf inflamosome, IL-beta, TNF-alpha, IL-6 and IL-8	Clinical trialNA	PMID25887490
IDOV_2976	Virus nameTanapoxvirus	Virus strainTPV-delta2L/delta66R/flic	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of 66R, 2L and insertion of flic gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismNude Foxn1 mice xenograft for HCT-116 (5.0E+6)	In-vivo virus concentration5 × 10⁶ pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to below 50mm after 36 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectTriggers activation of Ipaf inflamosome, IL-beta, TNF-alpha, IL-6 and IL-8	Clinical trialNA	PMID25887490
IDOV_2982	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2983	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result98% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2984	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result80% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2985	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result45% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2986	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration0.01 MOI	In-vitro result5% cell survival after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2987	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2988	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2989	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2990	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result5% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_2991	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+3 cells per well	In-vitro toxicityNA	AssayCell viability assay kit	In-vitro virus concentration1 MOI	In-vitro result100% cell death after 120 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3002	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 55 days	Mode of deliveryIntratumoral	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3004	Virus namePoxvirus	Virus strainCF33-hNIS	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationInsertion of gene encoding human hNIS	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with I-131	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHsd:athymic nude mice xenograft for HCT-116 (2.0E+6 cells)	In-vivo virus concentration1.0E+4 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 100mm after 55 days	Mode of deliveryIntravenous	Pathway inducedImmunogenicity followed by virus induced cell death	Immunogenic effectNA	Clinical trialNA	PMID31061881
IDOV_3072	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3073	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result5% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3074	Virus nameVaccinia virus	Virus strainDeltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result1% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3102	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻⁴ MOI	In-vitro result30% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3103	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻³ MOI	In-vitro result10% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3104	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line3.0E+5 cells per well	In-vitro toxicityNA	AssayTrypan blue assay	In-vitro virus concentration10⁻² MOI	In-vitro result1% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3117	Virus nameVaccinia virus	Virus strainVaccinia virus deltaJ2R/FCU1 VACV	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R gene and insertion of gene FCU1	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FC (200mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBD62 mice xenograft for Lovo cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to below 500 mm after 50 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3118	Virus nameVaccinia virus	Virus strainDeltaJ2R-I4L/FCU1 VACV (TG6002)	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of J2R and I4L gene and insertion of gene FCU1	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with 5-FC (200mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBD62 mice xenograft for Lovo cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to below 100 mm after 50 days	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID31011628
IDOV_3675	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3676	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result70% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3691	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3692	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3707	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell viability after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3708	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles virus in combination with mumps virus	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colon cancer cell line	Cell lineHCT-116	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after day 6	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29485292
IDOV_3775	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result30% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3776	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result38% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3777	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result44% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3778	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result55% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3779	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3780	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3781	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result62% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3782	Virus nameNewcastle disease virus	Virus strainNDVstrain 880	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result65% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3783	Virus nameNewcastle disease virus	Virus strainNDVstrain 14	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result70% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3784	Virus nameNewcastle disease virus	Virus strainNDVstrain 329	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result70% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3785	Virus nameNewcastle disease virus	Virus strainNDVstrain 485	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result80% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3786	Virus nameNewcastle disease virus	Virus strainNDVstrain 718	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result82% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3787	Virus nameNewcastle disease virus	Virus strainNDVstrain 53	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result85% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3788	Virus nameNewcastle disease virus	Virus strainNDVstrain 52	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result85% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3789	Virus nameNewcastle disease virus	Virus strainNDVstrain 746	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result85% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3790	Virus nameNewcastle disease virus	Virus strainNDVstrain 12	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result85% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3791	Virus nameNewcastle disease virus	Virus strainNDVstrain 49	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result90% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3792	Virus nameNewcastle disease virus	Virus strainNDVstrain 753	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result90% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3793	Virus nameNewcastle disease virus	Virus strainNDVstrain 777	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result95% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3794	Virus nameNewcastle disease virus	Virus strainNDVstrain 789	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result95% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3795	Virus nameNewcastle disease virus	Virus strainNDVstrain 27	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result95% cells viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3796	Virus nameNewcastle disease virus	Virus strainNDVstrain 48	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3797	Virus nameNewcastle disease virus	Virus strainNDVstrain 389	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3798	Virus nameNewcastle disease virus	Virus strainNDVstrain AD	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3799	Virus nameNewcastle disease virus	Virus strainNDVstrain 922	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3800	Virus nameNewcastle disease virus	Virus strainNDVstrain 945	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3801	Virus nameNewcastle disease virus	Virus strainNDVstrain 429	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3802	Virus nameNewcastle disease virus	Virus strainNDVstrain 339	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result100% cell viability after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3887	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result63% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3888	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3889	Virus nameNewcastle disease virus	Virus strainNDVstrain 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3890	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result69% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3891	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result55% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3892	Virus nameNewcastle disease virus	Virus strainNDVstrain 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result43% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3893	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result75% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3894	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result67% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3895	Virus nameNewcastle disease virus	Virus strainNDVstrain 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3896	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result64% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3897	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result59% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3898	Virus nameNewcastle disease virus	Virus strainNDVstrain 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result54% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3899	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result57% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3900	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result41% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3901	Virus nameNewcastle disease virus	Virus strainNDVstrain 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result37% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3902	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result37% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3903	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result32% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3904	Virus nameNewcastle disease virus	Virus strainNDVstrain 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result29% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3905	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result68% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3906	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result65% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3907	Virus nameNewcastle disease virus	Virus strainNDVstrain 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result62% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3992	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result62% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3993	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_3994	Virus nameNewcastle disease virus	Virus strainNDVwild 264	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4004	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result70% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4005	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4006	Virus nameNewcastle disease virus	Virus strainNDVwild 320	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result42% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4016	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result70% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4017	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result65% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4018	Virus nameNewcastle disease virus	Virus strainNDVwild 321	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4028	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result62% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4029	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result60% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4030	Virus nameNewcastle disease virus	Virus strainNDVwild 373	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result58% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4040	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result50% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4041	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result42% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4042	Virus nameNewcastle disease virus	Virus strainNDVwild 770	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4052	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result38% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4053	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result35% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4054	Virus nameNewcastle disease virus	Virus strainNDVwild 852	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result30% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4064	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration2 HAU	In-vitro result68% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4065	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration8 HAU	In-vitro result65% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4066	Virus nameNewcastle disease virus	Virus strainNDVwild 776	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState centre for virology and biotechnology, Russia	Origin of cell lineHuman colon carcinoma cell line	Cell lineHCT-116	Concentration of cell line10000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration16 HAU	In-vitro result62% cell survival after 4th day	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induces apoptosis, necrosis and autophagy in cancer cells	Immunogenic effectInduction of MARK signalling pathway	Clinical trialNA	PMID29621357
IDOV_4313	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result81.3 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4343	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4344	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4345	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4346	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4347	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result90% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4348	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4349	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4350	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4351	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4352	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration100 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4358	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with dbcAMP 100 micromoalr	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.001 MOI	In-vitro result40% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4359	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with dbcAMP 200 micromoalr	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.01 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_4360	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with dbcAMP 400 micromoalr	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal carcinoma	Cell lineHCT-116	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347
IDOV_5069	Virus nameAvian orthoreovirus	Virus strainARV-PB1	Virus genome typeRNA	Virus familyReoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman colorectal cancer cell line	Cell lineHCT-116	Concentration of cell line1.0E+3 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectInduction of Interferon related gene expression	Clinical trialNA	PMID28441762